Over the last decade, value-based reimbursement models have garnered a mountain of interest, but challenges in building a data infrastructure that can identify outcome metrics and logistics to dispense payments have largely relegated these models to anecdotal status. Recent deals by Pfizer and Takeda may indicate a step forward. Precision’s Ryan Cox weighs in on the evolving state of value based reimbursement models.

Read the full article here!